(Q41457277)

30 September 2017

title

Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma (English)

1 reference

30 September 2017

1 reference

Xiaohua Zhang

1

1 reference

30 September 2017

Xianjin Wang

2

1 reference

30 September 2017

Tianyuan Xu

3

1 reference

30 September 2017

Shan Zhong

4

1 reference

30 September 2017

Zhoujun Shen

5

1 reference

30 September 2017

publication date

11 February 2015

1 reference

30 September 2017

1 reference

30 September 2017

volume

36

1 reference

30 September 2017

issue

7

1 reference

30 September 2017

page(s)

5273-5281

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-015-3187-7

30 September 2017

exact match

0 references

cites work

Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

An expanding role for mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Where is mTOR and what is it doing there?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

mTOR kinase inhibitors as potential cancer therapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

mTOR signaling at a glance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Rapamycin inhibits mTORC1, but not completely.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Mechanisms of mTOR inhibitor resistance in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25666752

12 December 2020

inferred from PubMed ID database lookup

Malignant pheochromocytoma and paraganglioma: future considerations for therapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25666752

12 December 2020

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/25666752

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S13277-015-3187-7

1 reference

Dimensions Publication ID

30 September 2017

1001451104

0 references

Fatcat ID

release_zrp7mcfryvbfdiz3cljixkfsmy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zrp7mcfryvbfdiz3cljixkfsmy

24 November 2022

mapped directly with Wikidata item

1 reference